SVRA Stock Hits 52-Week Low After FDA Delays Decision On Lung Disease Drug Application

Savara said the FDA’s review of Molgramostim is ongoing, but did not provide a revised date for the decision.
Image for representational purpose. A view from lab as Ankara University Faculty of Pharmacy, Department of Basic Pharmaceutical Sciences.
Image for representational purpose. A view from lab as Ankara University Faculty of Pharmacy, Department of Basic Pharmaceutical Sciences.(Photo by Betul Abali/Anadolu via Getty Images)
Profile Image
Arnab Paul·Stocktwits
Published Nov 20, 2026   |   10:23 AM EST
Share
·
Add us onAdd us on Google
Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...
  • Molgramostim, proposed to be marketed as Molbreevi, is expected to treat autoimmune pulmonary alveolar proteinosis.
  • The FDA decision was initially set for August but later extended to November 22.
  • The company reported cash equivalents and short-term investments of about $173 million, as of June 30.

Advertisement|Remove ads.

Shares of Savara (SVRA) plunged 18% on Friday to their lowest level in just over a year, after the U.S. Food and Drug Administration (FDA) said it would not meet the November 22 deadline to decide on the company’s experimental lung disease treatment, Molgramostim.

The company said the FDA’s review remains ongoing, but did not provide a revised date for the decision. The delay does not mean that the FDA has issued a Complete Response Letter (CRL) or rejected the application.

SVRA shares are on track for their biggest single-day slump since May 2025.

Advertisement|Remove ads.

FDA’s Second Extension For Molbreevi

Molgramostim, proposed to be marketed as Molbreevi, treats autoimmune pulmonary alveolar proteinosis (PAP), a rare disease in which fatty, protein-rich material accumulates in the lungs, making breathing difficult. The inhaled treatment helps immune cells clear the accumulated material.

Savara’s Phase 3 Impala-2 trial met its primary endpoint, with data showing significant improvements in lung function after 24 weeks compared with placebo. The FDA granted priority review, with a decision initially set for August but later extended to November 22.

Molbreevi is Savara’s only clinical development program. The company reported cash equivalents and short-term investments of about $173 million, as of June 30.

Advertisement|Remove ads.

Last week, H.C. Wainwright initiated coverage with a ‘Buy’ rating and $10 price target, citing Molbreevi’s potential to become the first FDA-approved treatment for the disease.

JPMorgan initiated coverage in October with an ‘Overweight’ rating and $12 target, citing the drug’s blockbuster potential. The firm added that Molbreevi could receive approvals in the U.K. and European Union in the fourth quarter (Q4) of 2026 and the first quarter (Q1) of 2027.

Retail Remains 'Extremely Bullish'

Despite the slump, retail sentiment surrounding SVRA on Stocktwits remained ‘extremely bullish’ over the past 24 hours, amid ‘extremely high’ message volumes.

Advertisement|Remove ads.

SVRA (1).png

The stock has declined more than 29% so far in 2026.

Also read: SpaceX Lenders Reportedly Do Not Want Musk’s $40B AI Chips To Be Launched Into Orbit – SPCX Stock Falls Below IPO Price Pre-Market

Advertisement|Remove ads.

For updates and corrections, email newsroom[at]stocktwits[dot]com

Comments
Share your thoughts...

Comments posted here will also appear on symbol pages.

Follow on Google News
Read about our editorial guidelines and ethics policy

Advertisement|Remove ads.